Why the study?
Can a competitive enzyme immunoassay differentiate between pigs vaccinated with attenuated strains and those infected with wild-type Aujeszky's disease virus?
Can a competitive enzyme immunoassay differentiate between pigs vaccinated with attenuated strains and those infected with wild-type Aujeszky's disease virus?
A novel competitive enzyme immunoassay can successfully distinguish between pigs vaccinated with certain attenuated strains and those infected with wild-type Aujeszky's disease virus.
Answers are grounded in this paper and cite their sources.
May enable serological differentiation of vaccinated from infected pigs; leaves open prospective validation in control programs.
A competitive enzyme immunoassay was developed to detect antibodies to a glycoprotein (gI) of Aujeszky's disease virus. Infected cell monolayers were used as antigen and a monoclonal antibody directed against an epitope of gI as indicator antibody. It was demonstrated that pigs vaccinated with the Bartha, BUK or NIA-4 strains did not produce antibody to the epitope of gI, whereas all wild-type viruses tested did induce this antibody. The antibody to the gI epitope persisted for at least 15 weeks. The present test, which enables us to distinguish pigs vaccinated with certain attenuated strains from pigs infected with wild-type Aujeszky's disease virus, may be of great value in future combined vaccination-eradication programmes for Aujeszky's disease.
No takes yet. Share an insight, caveat, or question.
Oirschot et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: